Effects of TNF-α Inhibitors on Abdominal Adiposity in Patients with Inflammatory Rheumatic Diseases

Toussirot, Éric; Dumoulin, Gilles

doi:10.3899/jrheum.140912

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[41][42][43][44][45] On the other hand, TNFis might lead to an increase in body weight and a change in body composition. 46,47 A tendency toward a gain in visceral fat was observed by dualenergy x-ray absorptiometry in spondyloarthritis patients receiving TNFis. 46 In addition, obesity is long been considered a risk factor for aggravating existing psoriasis.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis

Yang

et al. 2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Background: Previous studies have suggested that biologic therapy for psoriasis might relate to body weight gain.Objective: To assess the changes in body weight and body mass index (BMI) in psoriasis patients after receiving various biologics.Methods: We conducted a systematic review and network meta-analysis to evaluate the changes in body weight and BMI in psoriasis patients receiving biologics. On March 1, 2019, we searched Medline, Embase, and Cochrane Central Register of Controlled Trials for relevant studies. The Newcastle-Ottawa scale was used to assess the risk of bias.Results: We included 6 studies with 862 psoriasis patients. Compared with conventional systemic treatments, treatment with tumor necrosis factor a inhibitors was associated with a significant increase in body weight (mean difference 1.40 kg, 95% confidence interval 0.88-1.93 kg) and BMI (0.39 kg/m 2 , 95% confidence interval 0.24-0.54 kg/m 2 ). In contrast, no significant increase in body weight or BMI was found among patients receiving anti-interleukin (IL)-12/23 or anti-IL-17 biologics.Limitations: Only 1 study reported body weight and BMI for patients receiving the anti-IL-17 biologic. Conclusion:Tumor necrosis factor a inhibitor treatment appears to be associated with an increase in body weight and BMI, and treatment with anti-IL-12/23 and anti-IL-17 biologics do not. This association should be considered before initiating biologics for overweight and obese patients.

show abstract

Section: Discussionmentioning

confidence: 96%

“…46,47 A tendency toward a gain in visceral fat was observed by dualenergy x-ray absorptiometry in spondyloarthritis patients receiving TNFis. 46 In addition, obesity is long been considered a risk factor for aggravating existing psoriasis. 48 The potential effect of TNFis on The present study has several limitations.…”

Section: Discussionmentioning

confidence: 96%